Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Monomethyl Auristatin E-Conjugated Antibody
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Axplora
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Novasep has successfully optimized and scaled-up the process of Adcitmer® (monomethyl auristatin E-conjugated antibody), McSAF Inside® Oncology’s first-in-class proprietary ADC to treat neuroendocrine cancers.
Brand Name : Adcitmer
Molecule Type : Large molecule
Upfront Cash : Undisclosed
November 18, 2021
Lead Product(s) : Monomethyl Auristatin E-Conjugated Antibody
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Axplora
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?